Pharma Industry Finland (PIF) supports the objectives of promoting a competitive and innovation-friendly environment for R&D in Europe and enhancing the availability and accessibility of medicines for patients. We encourage, in particular, the creation of structures for a faster marketing authorisation process, reducing unnecessary administrative burdens, and the introduction of a transferable exclusivity voucher as…
PIF
Pharma Industry Finland
Industry association · Finland
not in the EU Transparency RegisterThis organization files on consultations without a register number, so its record here is built from its filings alone. Register facts — staff, costs, accreditations — are not available for it.
2
positions filed
in the 583 files tracked
1
legislative file
of 583 tracked
0
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Track Pharma in PolicySpeak: request access →
Work at Pharma Industry Finland? so we know who speaks for it.
Their record over time
Pharma Industry Finland filed 2 positions on 18 Oct 2023, across 1 of the 583 legislative files tracked here.
What they argued
Pharma Industry Finland (PIF) supports the objectives of promoting a competitive and innovation-friendly environment for R&D in Europe and enhancing the availability and accessibility of medicines for patients. We encourage, in particular, the creation of structures for a faster marketing authorisation process, reducing unnecessary administrative burdens, and the introduction of a transferable exclusivity voucher as…
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Put Pharma Industry Finland next to another organization. Same files, same register facts, side by side. Compare →
Is this your organization?
Everything on this page comes from Pharma Industry Finland’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.